Treace Medical Concepts, Inc (TMCI) FinancialsTMCITreace Medical Concepts, Inc

Evaluating the bottom line, Treace Medical Concepts, Inc. maintains a gross margin of 78.47%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -32.96%, while the net margin is -34.98%. These profitability ratios, combined with a Return on Equity (ROE) of -71.99%, provide a clear picture of how effectively TMCI converts its operational activities into shareholder value.

In the context of the broader market, TMCI competes directly with industry leaders such as ANIK and SMTI. With a market capitalization of $292.63M, it holds a significant position in the sector. When comparing efficiency, TMCI's gross margin of 78.47% stands against ANIK's 65.15% and SMTI's 90.76%. Such benchmarking helps identify whether Treace Medical Concepts, Inc. is trading at a premium or discount relative to its financial performance.

Treace Medical has shown a gross margin of 78.47% in the latest quarter, which is relatively strong, but it continues to report significant net losses, with a net income of -$15,873,000 in Q2 2026. The company has a current ratio of 2.90, indicating it can cover its short-term liabilities, but the debt to equity ratio has risen to 87.41%, suggesting increasing financial risk.